Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9UGC6
UPID:
RGS17_HUMAN
Alternative names:
-
Alternative UPACC:
Q9UGC6; Q5TF49; Q8TD61; Q9UJS8
Background:
Regulator of G-protein signaling 17 (RGS17) plays a pivotal role in modulating G protein-coupled receptor (GPCR) signaling pathways. It specifically regulates signaling via muscarinic acetylcholine receptor CHRM2 and dopamine receptor DRD2 by increasing the GTPase activity of G protein alpha subunits, leading them into their inactive GDP-bound form. This protein has a selective affinity for GNAZ and GNAI2 subunits, enhancing their GTPase activity and modulating their signaling activities. Additionally, RGS17 negatively impacts mu-opioid receptor-mediated G-protein activation.
Therapeutic significance:
Understanding the role of Regulator of G-protein signaling 17 could open doors to potential therapeutic strategies, particularly in disorders related to GPCR signaling such as neurological diseases and addiction.